The EU will experience the biggest reform to its pharmaceutical laws in 20 years under what is known as the “EU Pharma Package”.
In this session (hosted by LES USA-Canada), the key changes (including regulatory exclusivities and incentives, and the bolar exemption) will be covered, and how they will impact the legal and commercial landscape for pharmaceutical and biotech companies operating in Europe, including attention to its consequences on the licensing business.
Speakers:
